Medtech startups face multiple risks and challenges as they struggle to bring their products to market, which means many live-saving technologies never reach patients in need. For this reason, the Darwinian/survival-of-the-fittest environment that tech startups typically compete within can be counterproductive for the medtech industry and patients – as the most beneficial technologies don’t always survive. The Fogarty Institute for Innovation, a nonprofit based in Silicon Valley, has created a non-Darwinian environment where carefully-selected medtech startups are given time, space and support to survive and thrive as independent companies in the risk intensive medtech ecosystem.
The panel includes:
Andrew Cleeland, VP and general manager of Medtronic’s Transcatheter Mitral Valve Venture; board member of the Fogarty Institute for Innovation
Anne Morrissey, CEO of InPress Technologies, a Fogarty Institute company
Sergio Aguirre, founder and CTO of EchoPixel, a Fogarty Institute company
Shin Kosuga, director of Healthcare Business for Mitsubishi Corporation (Americas)
Moderated by Prachie Banthia.